Potential benefits of estrogens and progestogens on breast cancer

International Journal of Fertility and Women's Medicine

Volumn 43, Issue 6, 1998, Pages 278-285

  Schneider, H P G ^a   Jackisch, C ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b NONE

Author keywords

Breast cancer; Epidemiology; Estrogens; Hormone replacement therapy; Progestins; Progestogens; Steroid receptors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; GROWTH FACTOR; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; NANDROLONE; NORGESTREL; PLACEBO; PROGESTERONE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; BREAST CELL; CANCER RISK; CELL PROLIFERATION; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTO ONCOGENE; RAT; REVIEW;

ADULT; AGED; BREAST; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; PREGNANCY; PROGESTERONE;

EID: 0032434279     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. The World Health Report 1997; Conquering suffering, enriching humanity. WHO, May 5, 1997. ISBN 92 4 156185 8.
2. Parker SL, Tang T, Boden S, et al: Cancer statistics 1996. CA Cancer J Clin 46:29-45, 1996.
3. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047-1059, 1997.
4. Willis DB, Calle EF, Miracle McMahill HL, et al: Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 7:449-457, 1996.
5. Sutherland RL, Lee CSL, Cornish AL, et al: Progestin regulation of cell proliferation in the breast and endometrium, in Baird DT et al (eds): Organ Selective Action of Steroid Hormones. Berlin, Springer, pp 85-105, 1995.
6. Thomas DB: Do hormones cause breast cancer? Cancer 53:595-604, 1984.
7. King RJB: A discussion of the roles of oestrogen and progestin in human mammary carcinogenesis. J Steroid Biochem Mol Biol 39:811-818, 1991.
8. Tonilo PG, Levitz M, Zelenjuch-Jacquotte A, et al: A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 87:190-197, 1995.
9. Berrino F, Muti P, Micheli A, et al: Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 88:291-296, 1996.
10. Cauley JA, Lucas FL, Kuller LH, et al, for the Osteoporotic Fractures Research Group: Bone mineral density and risk of breast cancer in older women. JAMA 276:611-617, 1996.
11. Zhang Y, Kiel DP, Kreger BE, et al: Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 336:611-617, 1997.
12. Clocca DR, Vargas Rolg LM: Estrogen receptors in human target tissues: Biological and chemical implications. Endocr Rev 16:35-62,1995.
13. Ferguson DJP, Anderson TJ: Morphological evaluation of cell turnover in relation to the menstrual cycle in the resting human breast. Br J Cancer 44:177-181, 1981.
14. Vogel PM, Geogiade NG, Fetter BE, et al: The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol 104:23-34, 1981.
15. Sitruk-Ware R: Estrogens, progestins and breast cancer risk in postmenopausal women: state of the ongoing controversy in 1992. Maturitas 15:129-139, 1992.
16. Wren BG: Hormonal replacement therapy and breast cancer. Eur Menopause J 2:13-19, 1995.
17. Wren BG, Eden JA: Do progestogens reduce the risk of breast cancer? A review of the evidence. Menopause 3:4-12, 1996.
18. Musgrove EA, Lee CSI, Sutherland RL: Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor, epidermal growth factor receptor, c-fos and c-myc genes. Mol Cell Biol 11:5032-5043, 1991.
19. Malet C, Gompel A, Yaneva A, et al: Estradiol and progesterone receptors in cultured normal human breast epithelial cells and fibroblasts: Immunocytochemical studies. Clin Endocrinol Metab 73:8-17, 1991.
20. Cullen KJ, Lippmann ME: Estrogen regulation of protein synthesis and cell growth in human breast cancer. Vitam Horm 45:127-172, 1989.
21. Jones C, Ingram D, Mattes E, et al: The effect of hormone replacement on prognostic indices in women with breast cancer. Med J Aust 161:106-110, 1994.
22. Anderson TJ: Effects on breast tissue of exogenous estrogen and progestogens. Acta Obstet Gynecol Scand 134(Suppl):9-16, 1986.
23. Russo J, Russo IH: Hormonally induced differentiation: A novel approach to breast cancer prevention. J Cell Biochem 22(Suppl):58-64, 1995.
24. McManus MJ, Welsch CW: The effect of estrogen, progesterone, thyroxine, and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice. Cancer 54:1920-1927, 1984.
25. Chang KJ, Lee TTY, Linares-Cruz G, et al: Influence of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 63:785-791, 1995.
26. Maudelonde T, Lavaud P, Salazar G, et al: Progestin treatment depresses oestrogen receptor but not cathepsin D levels in needle aspirates of benign breast disease. Breast Cancer Res Treat 19:95-102, 1991.
27. Foidart JM, Colin C, Denoo X, et al: Influence of percutaneous administration of estradiol and progesterone on the proliferation of human breast epithelial cells, in Calvo F, Crépin M, Magdelenat H (eds): Breast Cancer, Advances in Biology and Therapeutics. London, John Libbey Eurotext, pp 329-334, 1996.
28. Desreux J, Noël A, Thomas JL, et al: Progestin induced apoptosis of normal human breast cells: An in vivo and in vitro study, in Wren BG (ed): Progress in the Management of the Menopause. Proceedings of the 8th International Congress on the Menopause, Sydney, Australia. New York, London, Parthenon Publishers, p 97, 1996.
29. Sitruk-Ware R, Plu-Bureau G: Progestogen use and breast cancer, in Wren BG (ed): Progress in the Management of the Menopause. Proceedings of the 8th International Congress on the Menopause, Sydney, Australia. New York, London, Parthenon Publishing, pp 203-210, 1996.
30. Catherino WH, Jeng MH, Jordan VC: Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 67:945-952, 1993.
31. Catherino WH, Jordan VC: Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 55:239-246, 1995.
32. Gambrell RD, Jr, Maier R, Sanders B: Decreased incidence of breast cancer in postmenopausal oestrogen and progestogen? Obstet Gynecol 62:435-443, 1983.
33. Nachtigall MJ, Smiler SW, Nachtigall R, et al: Incidence of breast cancer in a 22 year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 80:827-830, 1992.
34. Ewertz M: Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 42:832-838, 1988.
35. Colditz GA, Hankinson SE, Hunter DJ, et al: The use of oestrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589-1593, 1995.
36. Newcomb PA, Longnecker MP, Storer BE, et al: Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 142:788-795, 1995.
37. Stanford JK, Weiss NS, Voigt LF, et al: Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. J Am Med Assoc 274:137-142, 1995.
38. Plu-Bureau G, Lê M, Sitruk-Ware R, et al: Progestogen use and the decreased risk of breast cancer in a cohort of premenopausal women with benign breast disease. Br J Cancer 70:270-277, 1994.
39. Schairer C, Byrne C, Keyl PM, et al: Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 5:491-500, 1994.
40. Jackisch C, Schneider HPG: Biological effects of estrogen and progestogen on human breast carcinogenesis. Menopause Rev 2:26-34, 1997.
41. The Women's Health Initiative Study Group: Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials 19:61-109, 1998.